These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15136970)

  • 21. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105
    [No Abstract]   [Full Text] [Related]  

  • 23. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy.
    von Haehling S; Sandek A; Anker SD
    J Am Geriatr Soc; 2005 Nov; 53(11):2030-1. PubMed ID: 16274392
    [No Abstract]   [Full Text] [Related]  

  • 27. Control of hypertension in patients with peripheral artery disease.
    Clement DL
    Blood Press; 2006; 15(4):251-2. PubMed ID: 17078187
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiology patient page. What is an angiotensin converting enzyme inhibitor?
    Sweitzer NK
    Circulation; 2003 Jul; 108(3):e16-8. PubMed ID: 12876137
    [No Abstract]   [Full Text] [Related]  

  • 29. Improving cardiovascular health outcomes through the use of evidence-based medicine.
    Douglas J
    Ethn Dis; 2005; 15(2 Suppl 2):S23-6. PubMed ID: 15822833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASCOT - more than a horse race!
    Kjeldsen SE; Narkiewicz K; Hedner T
    Blood Press; 2005; 14(5):262-3. PubMed ID: 16257870
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
    Baer JT; Sauer WH; Berlin JA; Kimmel SE
    Am J Cardiol; 2004 Aug; 94(4):479-81. PubMed ID: 15325933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 34. [Current indications for the treatment with angiotensin-converting enzyme inhibitors].
    Orte Martínez LM
    Rev Clin Esp; 1996 Jun; 196(6):345-6. PubMed ID: 8767066
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy with ACE inhibitors. What kind of risk make them indispensible?].
    Kleber FX
    MMW Fortschr Med; 2000 Nov; 142(46):44-5. PubMed ID: 11132312
    [No Abstract]   [Full Text] [Related]  

  • 36. [Angiotensin converting enzyme inhibitors. Increasing importance in the treatment of hypertension].
    Januszewicz A; Lapiński M
    Kardiol Pol; 1992 Dec; 37(12):393-7. PubMed ID: 1293350
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is ethnicity a factor in choice of antihypertensive drug?
    Bakris G
    Postgrad Med; 2005 May; 117(5):40. PubMed ID: 15948367
    [No Abstract]   [Full Text] [Related]  

  • 39. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 40. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.